"Pharma R&D set to endure despite rising MFN costs" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The number of “innovation champions” in the pharma industry working on infectious diseases is dropping — and that’s troubling ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Deal announcements often showcase where the stars align in ...

The pharmaceutical industry has immense pressure to deliver advanced and novel therapies to patients worldwide but faces monumental challenges in drug development. On average, the journey from ...

Iris brings over 30 years of global leadership in clinical development, regulatory strategy, and pharmaceutical R&D execution. From 2008 to 2024, she served as Executive Vice President, Chief Medical ...

Research and development (R&D) spending by drug manufacturers flatlined in 2022, according to data released by Evaluate Vantage Friday morning. Among the world’s largest 11 drugmakers, only ...

The initiative, backed by a total financial outlay of Rs 5,000 Crore (nearly $600 million) spanning from FY 2023-24 to FY ...

Pharmaceutical drug discovery and development have grown increasingly difficult over the years. Yes, there have been great breakthroughs in technology that can facilitate research processes and the ...

Pharmacists deliver life-changing healthcare. Their compassionate guidance educates patients on how to make the safest and best use of their prescribed medications. The University of Wyoming School of ...